Status:
RECRUITING
E3 Hypertension - A Team-based, Multidisciplinary Model in Addressing Barriers to Hypertension Control
Lead Sponsor:
Rush University Medical Center
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to compare a multidisciplinary clinical hypertension and social needs intervention to enhanced standard of care for hypertension management in primary care clinics with regards to hype...
Detailed Description
Cardiovascular disease (CVD) is the leading cause of death in the US as well as in Chicago. Risk factors for CVD include hypertension, diabetes, and lifestyle factors such as smoking, diet, and obesit...
Eligibility Criteria
Inclusion
- Adults 18 years or older
- African American and/or Latinx
- Uncontrolled stage 2 hypertension, BP \>/= 140/90
- Patient is following with Rush primary care provider in eligible Rush primary care clinics
- Patient has a smart phone (Android or iOS)
- Patient has an email
Exclusion
- Organ transplant recipient
- On dialysis
- Patient is already participating in another remote hypertension monitoring program
- Patient is not interested in participating in the program
- Patient has already participated in the E3 Hypertension program or the E3 Diabetes program
Key Trial Info
Start Date :
February 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06899750
Start Date
February 10 2025
End Date
October 1 2026
Last Update
September 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612